RLAY

Current Thesis

RLAY is a binary-catalyst precision-oncology setup into ASCO 2026 (abstract titles 2026-05-23, event late-May/early-June) and Q1 earnings (~2026-05-07). Two-way sell-side split (Barclays $21 Overweight 2026-04-08 vs. Jones Trading $18 Hold 2026-04-14) confirms the market hasn't priced a direction yet — RLY-2608 PI3Kα breast-cancer data is the binary. Not a trend trade, not a compounder. Event trade only, and only if price structure confirms narrative flow before the print. DORMANT until price shows hand.

Bull Case

• Barclays raised PT to $21 on 2026-04-08 (Overweight, reiterated) — incremental conviction ahead of RLY-2608 (mutant-selective PI3Kα) HR+/HER2+ breast cancer data updates expected 2026 ASCO window.
• RLY-2608 tolerability differentiation vs. Novartis alpelisib (lower hyperglycemia) — if combo-with-fulvestrant data prints ORR ≥30% in PIK3CA-mutant HR+ breast cancer, unlocks multi-billion TAM in 2L+ MBC.
• Q4 2025 print (2026-02-27) reported ~$700M cash → runway into 2027 at current $300M/yr burn — no forced dilution overhang before the data. That's the setup biotech bulls want: binary event + funded runway.
• Theme membership: biotech-precision-therapeutics cohort flagged ACCELERATING on 2026-04-19 theme discovery — sector beta supports a risk-on move into ASCO abstract release.
• High short interest (last read ~40% of float per prior dossier — needs refresh) = classic squeeze fuel if RLY-2608 abstract is accepted as oral (not poster) on the 2026-05-23 title drop.

Bear Case

• Jones Trading Hold initiation 2026-04-14 at $18 PT — a fresh second-look analyst sees the risk/reward as balanced. Split coverage within 6 days is a tell: nobody on the sell-side has a differentiated view, meaning data is the only catalyst that moves this.
• RLY-4008 (FGFR2) licensed to Elevation Oncology in 2025 — royalty stream won't hit 2026 P&L meaningfully. Second-asset optionality is deferred.
• Cash burn ~$300M/yr. If Q1 2026 print (~2026-05-07) shows burn acceleration >$85M for the quarter, runway story cracks and the 2027 raise becomes a H2-2026 raise — that's an immediate ~15-20% re-rate lower on clinical small-cap biotech comps.
• Competitive: Scorpion Therapeutics (STX-478) and Lilly's selective PI3Kα program are closing the differentiation gap through mid-2026. Clean competitor data BEFORE RLY-2608 print = moat erosion priced in immediately.
• Precision oncology ASCO trades historically: "buy the abstract, sell the oral" pattern means the trade is the 2026-05-23 → early-June window, NOT holding through the oral data.

Setup & Price Structure

• No live price context provided this run. Analyst PT range $18 (Jones, 2026-04-14) — $21 (Barclays, 2026-04-08) brackets the sell-side consensus zone.
• Pending at next refresh: 50DMA, 200DMA, short interest % float, price vs. $18 floor, 20-EMA weekly, volume vs. 20-day avg.
• Key levels to establish when price context returns: reclaim of $18 (Jones floor) on rising volume = first trigger; breakout >$21 (Barclays ceiling) on 2x volume = narrative confirmation / potential squeeze ignition.
• DORMANT. No fresh entry without: (1) price above 50DMA, (2) volume confirmation on any move through $18 or $21, (3) clean trend structure 2+ weeks pre-ASCO title drop.

Catalyst Calendar (next 30 days)

• ~2026-05-07 (±3 trading days): Q1 2026 earnings call. Watch cash position, quarterly burn, RLY-2608 enrollment update, guidance on ASCO abstract acceptance. BINARY — do NOT hold through print without a hedge.
• 2026-05-23 (hard date): ASCO 2026 abstract titles release. Oral vs. poster designation is the single biggest narrative signal of the month. Oral for RLY-2608 combo = bull case confirmed; poster-only = second-tier.
• Mid-May 2026 (est. ~2026-05-15): AACR 2026 post-conference readthroughs — watch for competitor PI3Kα data from Scorpion (STX-478) or Lilly.
• No FDA PDUFA actions scheduled within 30-day window.

What Would Change Our Mind

• Upgrade DORMANT→ACTIVE (size MEDIUM): ASCO abstract titles drop 2026-05-23 shows RLY-2608 combo as oral presentation AND stock reclaims $21 on volume >2x 20-day. Enter on retest of breakout level.
• Upgrade to HIGH: Q1 print (~2026-05-07) confirms cash >$620M (burn under control) + RLY-2608 enrollment ahead of plan + price structure intact above 50DMA. Data call becomes asymmetric.
• Kill thesis / SKIP: Q1 shows cash <$550M (runway compression to <18 months) OR Scorpion STX-478 prints ORR ≥35% with cleaner tox at AACR before RLY-2608 — differentiation moat gone, sell-side cuts within a week.
• Trim/avoid entirely: Weekly close below $14 with no data catalyst inside 60 days, or the sector SPDR biotech (XBI) loses its own 200DMA — binary oncology names bleed first on sector outflow.
• Pre-earnings discipline: If we're long and it's ≤3 trading days to ~2026-05-07 print, reduce to tracking position or flatten. Binary prints aren't edge.

Correlation Notes

Direct-comp and sector-beta watchlist:

• SCPS (Scorpion Therapeutics) — direct PI3Kα competitor. Inverse correlation on head-to-head clinical differentiation, positive on sector sentiment.
• KYMR (Kymera) — small-cap precision oncology peer, same sector beta.
• RXRX (Recursion) — AI-driven drug-discovery cohort overlap, separate narrative.
• XBI (sector ETF) — if XBI rolls under 200DMA, all small-cap binary biotech trades are risk-off regardless of company-specific setup.
• SRPT, VKTX — precision therapeutics cohort benchmarks for relative strength / theme health check.

Watch XBI direction into the 2026-05-23 ASCO abstract drop. If sector is red into the event, expect lower post-event volatility and a higher probability of "sell the news" outcome.